Anna Rowe

Medicine & Life Sciences

1. Alkaline Phosphatase 15%
2. Arm 11%
3. Biomarkers 8%
4. Blood Vessels 20%
5. C-Reactive Protein 24%
6. Clinical Trial Protocols 20%
7. Clinical Trials 9%
8. Congresses 7%
9. Coronavirus 33%
10. Ethics 11%
11. Feasibility Studies 13%
12. Fibrosis 6%
13. Health Care Outcome Assessment 10%
14. Health Status 7%
15. Immunomodulation 10%
16. Infections 5%
17. Inflammation 7%
18. Infliximab 31%
19. Interviews 7%
20. Liver 5%
21. Liver Cirrhosis 9%
22. Liver Diseases 10%
23. Macrophages 6%
24. Monoclonal Antibodies 13%
25. Monocytes 7%
26. namilumab 63%
27. National Institutes of Health (U.S.) 6%
28. Patient Care 7%
29. Patient Participation 5%
30. Patient Reported Outcome Measures 29%
31. Peer Review 5%
32. Phase II Clinical Trials 18%
33. Pneumonia 12%
34. Polymerase Chain Reaction 5%
35. Proteins 12%
36. Public Health 6%
37. Publications 9%
38. Research Ethics Committees 16%
39. Reverse Transcription 7%
40. Safety 15%
41. SARS Virus 26%
42. Sclerosing Cholangitis 56%
43. Serum 7%
44. Standard of Care 25%
45. Therapeutics 12%
46. Thorax 6%
47. timolumab 100%
48. Wounds and Injuries 5%
49. X Ray Computed Tomography 10%